NVCR OVER 200% of potential upsideOver 200% of potential upside, oversold and extreme RSI divergence on the weekly.
Now price is retesting the broken descending wedge
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−30.96 MXN
−3.52 B MXN
12.62 B MXN
98.79 M
About NovoCure Limited
Sector
Industry
CEO
Ashley Cordova
Website
Headquarters
St. Helier
Founded
2000
ISIN
JE00BYSS4X48
FIGI
BBG012FDDTJ1
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Related stocks
NovoCure Limited (NVCR) to rally 100% ??** short term forecast, days and weeks ahead **
On the above 10 day chart price action has crashed 95% since support failed. Today sellers are trying to push that correction to 100%, are they right?
Unlikely.
1) Price action (not visible on LOG) and RSI resistance breakouts.
2) Support on past r
NVCR CUP AND HANDLENVCR is seriously oversold and has potential for a reversal here. Could be the start of a fresh uptrend. We are currently completing a cup and handle reversal pattern. We have just broken out of the handle. Wait for pullback or enter right away. First target marked on chart as is stop loss. I am ope
NVCR ( Day trade short )watch this level for a day trade short, this stock is up massively on the day and this should be the rejection point
NVCR long Like the volume and the high wave indecision candle.
Great spacing between the moving averages, offering great risk reward.
Looking for a pull back to get in with a limit buy
NVCRNuovo cure consolidating under 200 dma , but above 65 ema , Pradeep Bonde says 65 ema cross is better then 200 ema
Long short term / short long termKeeping it simple here. Given the current market conditions, it could play out in a h&S pattern with a target of around 15 bucks. What do you think?
NVCR ready to go on an extended run Initial Target by Apr 14 = 99
Target Range by 5/20/2022 = 108-116
Upcoming earnings as a catalyst. Bullish Momentum for pre-earnings run up.
Kept the chart simple but a lot of bullish aspects at play here, to name a few:
- ready for markup coming off an accumulation phase
- completes wave 5 corre
NVCR primed for an extended runKept the chart simple but there are a lot of bullish aspects at play here:
- ready for markup after an accumulation phase
- coming off a wave 5 correction apprx. 0.786 off the highs last June
- looking at weekly chart you’ll see a larger running flat structure
- earnings as a catalyst and overall
NVCR - SwingSwing trade - longer term. Could enter between 90/92 or wait for more bullish momentum and catch it on the pullback.
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange NOVOCURE LIMITED stocks are traded under the ticker NVCR/N.
NVCR/N stock has risen by 0.10% compared to the previous week, the month change is a 0.10% rise, over the last year NOVOCURE LIMITED has showed a 0.10% increase.
We've gathered analysts' opinions on NOVOCURE LIMITED future price: according to them, NVCR/N price has a max estimate of 784.76 MXN and a min estimate of 529.71 MXN. Watch NVCR/N chart and read a more detailed NOVOCURE LIMITED stock forecast: see what analysts think of NOVOCURE LIMITED and suggest that you do with its stocks.
NVCR/N stock is 0.61% volatile and has beta coefficient of 1.23. Track NOVOCURE LIMITED stock price on the chart and check out the list of the most volatile stocks — is NOVOCURE LIMITED there?
Today NOVOCURE LIMITED has the market capitalization of 35.53 B, it has decreased by −12.82% over the last week.
Yes, you can track NOVOCURE LIMITED financials in yearly and quarterly reports right on TradingView.
NOVOCURE LIMITED is going to release the next earnings report on Jul 24, 2025. Keep track of upcoming events with our Earnings Calendar.
NVCR/N earnings for the last quarter are −6.35 MXN per share, whereas the estimation was −9.51 MXN resulting in a 33.20% surprise. The estimated earnings for the next quarter are −7.28 MXN per share. See more details about NOVOCURE LIMITED earnings.
NOVOCURE LIMITED revenue for the last quarter amounts to 3.18 B MXN, despite the estimated figure of 3.01 B MXN. In the next quarter, revenue is expected to reach 2.93 B MXN.
NVCR/N net income for the last quarter is −703.10 M MXN, while the quarter before that showed −1.37 B MXN of net income which accounts for 48.84% change. Track more NOVOCURE LIMITED financial stats to get the full picture.
No, NVCR/N doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 21, 2025, the company has 1.49 K employees. See our rating of the largest employees — is NOVOCURE LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVOCURE LIMITED EBITDA is −3.16 B MXN, and current EBITDA margin is −25.83%. See more stats in NOVOCURE LIMITED financial statements.
Like other stocks, NVCR/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVOCURE LIMITED stock right from TradingView charts — choose your broker and connect to your account.